Monoclonal Antibody Treatment for COVID-19
With the emergence of the Omicron variant, which is now the dominant variant in United States, has come resistance to commercially available monoclonal antibody for COVID-19, excluding Sotrovimab. The federal government allocates this medication and we are working to secure monoclonal antibody treatment, however, we currently do not have supply of this pharmaceutical at this time. If and when monoclonal antibody treatment becomes available at Northern Arizona Healthcare, this page will be updated with the necessary information for community providers to refer their patients for monoclonal antibody treatment. If you have questions on whether or not you may qualify for this treatment, contact your primary care provider.
Click the button below for more information from the Arizona Department of Health Services on COVID-19 antivirals.